ClinicalTrials.gg
CompletedNCT05820100Updated Jan 5, 2024

Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT

An observational study in Retinitis Pigmentosa and Retinal Dystrophy, sponsored by Nanoscope Therapeutics Inc.. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Nanoscope Therapeutics Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
35
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 43 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.

Enrollment
30th of 38
35 · median 73
Started
2023
with 4 others
Observational
39 of 119
11 open now
Registered
103rd of 119
by date
Lead sponsor
3 of 119
Nanoscope Therapeutics Inc.

Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the 30th largest by enrollment of the 38 observational ones that give a count, is one of 5 that started in 2023, is one of 39 observational ones, and was the 103rd registered.

Retinitis Pigmentosa

281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.

Browse Retinitis Pigmentosa studies →

Open to participants now

20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Retinitis Pigmentosa studies recruiting now, 38 (76%) set no upper age limit and 6 (12%) stop at 75 or younger; 16 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies in Retinitis Pigmentosa with a site in United States, or all of them as a file.
02

Study summary

This is a prospective Multi-Center Observational Study to assess the reliability and validity of the Multi-Luminance Y-Mobility Test (MLYMT) and Multi-Luminance Shape Discrimination Study (MLSDT) Main Outcome Measures: (i) Performance scores in normal and severely visually impaired subjects with a clinical diagnosis of retinitis pigmentosa (RP) on MLYMT and MLSDT at multiple luminance levels and (ii) reliability and content validity of MLYMT and MLSDT.

Read the detailed description

Two assessment visits will be conducted in order to evaluate functional visual performance in severely vision impaired subjects with RP and normally sighted subjects. Two visits will occur at week 0 and week 4 with functional vision assessments occurring at both visits in order to assess visit-to-visit variability. For the MLYMT, navigational vision will be assessed using each eye and binocularly at up to 6 different light levels (range 0.3 to 100 lux). Subjects will also perform the Multi-Luminance Shape Discrimination Test (MLSDT) which assesses near object recognition under different lighting levels. MLYMT and MLSDT performance will be evaluated together with Best Corrected Visual Acuity (BCVA), Visual Field (VF) and responses to visual function questionnaires. Subjects will be assigned to one of two cohorts based on presence or absence of RP in addition to BCVA performance.

03

Conditions studied

  • Retinitis Pigmentosa
  • Retinal Dystrophy

Keywords

  • Retinitis Pigmentosa
  • Inherited Retinal Diseases
  • Eye Diseases
  • Retinal Degeneration
  • Mobility Test
  • Multi-luminance Y- Mobility Test
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This study will enroll approximately 35 adult subjects, to one of 2 cohorts. Subjects who meet all the inclusion criteria and for whom none of the exclusion criteria apply will be eligible for enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Able to comprehend and give .
  3. Able to comply with testing and all protocol tests.
  4. Eligible for 1 of 2 cohorts listed below:

Cohort 1: Normally Sighted Participants with clinically normal ocular findings and BCVA better than logMAR 0.3 (as confirmed by ETDRS letter score > 73) in each eye Cohort 2: Severely Sight Impaired Participants with BCVA no better than logMAR 1.6 in better seeing eye, and worse than LogMAR 1.9 in the worse seeing eye, and a clinical diagnosis of advanced RP

Exclusion criteria

Exclusion Criteria:

  1. Concurrent participation in any interventional clinical trial or receipt of an drug within the previous 6 months
  2. Presence of any condition other than RP Disease that impairs visual acuity or visual fields e.g., visually significant cataract or visual field loss in glaucoma
  3. Presence of neurological condition that impairs visual acuity or visual field, e.g., hemianopia secondary to stroke
  4. Individuals who refuse or are incapable of performing mobility testing
  5. Individuals with retinal prosthesis (such as ARGUS-II)
  6. Participation in Nanoscope studies NTXMCO-002 (RESTORE) or NTXMCO-004 (STARLIGHT)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
35 participants (actual)
Patient registry
No

Groups and cohorts

  • Normally Sighted

    Participants with clinically normal ocular findings and BCVA better than logMAR 0.3 in each eye.

    Other: Observational

  • Severely Sight Impaired

    Participants with BCVA no better than logMAR 1.6 in better seeing eye, and worse than logMAR 1.9 in the worse seeing eye, and a clinical diagnosis of advanced RP

    Other: Observational

Interventions

  • OtherObservational

    The goal of this observational study is to assess the reliability and validity of the multi-luminance Y-Mobility Test (MLYMT) and multi-luminance shape description test (MLSDT) for evaluation of subjects with severe vision impairment due to RP. Normally sighted subjects will provide a control group. The MLYMT consists of two LED panels, one of which is illuminated at multiple luminance levels, positioned at the end of Y-configuration. Seven obstacles are placed ahead of the panels, which the test subject should detect and avoid before reaching and touching the lit panel.

06

What researchers measure

Primary outcomes

  1. MLYMT scores in normal and severely visually impaired subjects with a clinical diagnosis of RP on MLYMT

    A higher MLYMT score (range -1 to 5) indicates better navigational vision.

    Time frame: 4 Weeks

  2. MLSDT scores in normal and severely visually impaired subjects with a clinical diagnosis of RP on MLSDT

    A higher MLSDT score (range 0 to 5) indicates greater shape discrimination ability at lower luminance level

    Time frame: 4 Weeks

  3. Reliability and construct validity of MLYMT

    Evaluation of the performance (test-retest reliability) of the test(s) based on the visual acuity

    Time frame: 4 Weeks

  4. Reliability and construct validity of MLSDT

    Evaluation of the performance (test-retest reliability) of the test(s) based on the visual acuity

    Time frame: 4 Weeks

07

Study locations

8 sites
  • Nanoscope Clinical Site
    Phoenix, Arizona 85020, United States
  • Nanoscope Clinical Site
    Beverly Hills, California 90211, United States
  • Nanoscope Clinical Site
    Miami, Florida 33136, United States
  • Nanoscope Clinical Site
    Fargo, North Dakota 58103, United States
  • Nanoscope Clinical Site
    Bellaire, Texas 77401, United States
  • Nanoscope Clinical Site
    McAllen, Texas 78503, United States
  • Nanoscope Clincal Site
    San Antonio, Texas 78240, United States
  • Nanoscope Clinical Site
    Arecibo, 00612, Puerto Rico
08

References and documents

Individual participant data

Plan to share: Yes — The results of the clinical trial will be made available when the study is completed. The results will be published on this site and be available to conference presentations and publications.

Time frame: 12 months after the study is completed

Access criteria: Reliability and Validity of MLYMT and MLSDT

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Oct 2023, 5 months.

Of 49 observational studies under Retinitis Pigmentosa, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 23. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2023
First posted
Apr 19, 2023
StartActual
Apr 25, 2023
Primary completionActual
Oct 17, 2023
CompletionActual
Oct 17, 2023
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05820100
Lead sponsor
Nanoscope Therapeutics Inc.
Responsible party
Sponsor
First posted
Apr 19, 2023
Start date
Apr 25, 2023
Primary completion
Oct 17, 2023
Completion
Oct 17, 2023
Last update
Jan 5, 2024

Study contacts

Dr Samarendra Mohanty
study chair · Nanoscope Therapeutics Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion